Blog
RSS FeedPosted by Michael Wonder on 08 May 2024
Selinexor with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma after 4 or more treatments
8 May 2024 - NICE has published evidence-based recommendations on the use of selinexor (Nexpovio) in combination with dexamethasone for ...
Posted by Michael Wonder on 03 May 2024
Improved deal signals NICE recommendation of sickle cell treatment voxelotor
3 May 2024 - Around 4,000 people with sickle cell disease could benefit from a new treatment recommended by NICE ...
Posted by Michael Wonder on 03 May 2024
NHS rolls out ‘life-changing’ treatment for thousands with sickle cell disease
3 May 2024 - Thousands of patients with sickle cell disorder are to be offered a new “life-changing” treatment on ...
Posted by Michael Wonder on 01 May 2024
Selpercatinib for the treatment of patients with advanced thyroid cancer with RET alterations that has not been treated with systemic therapy
1 May 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 May 2024
Pembrolizumab for the treatment of patients 3 years and older with relapsed or refractory classical Hodgkin's lymphoma
1 May 2024 - NICE has published updated evidence-based recommendations on the pembrolizumab (Keytruda) for the treatment of patients with ...
Posted by Michael Wonder on 30 Apr 2024
Gefapixant for the treatment of patients with refractory or unexplained chronic cough
30 April 2024 - NICE is unable to make a recommendation on the use of gefapixant (Lyfnua) for the treatment of ...
Posted by Michael Wonder on 29 Apr 2024
Idebenone for the treatment of patients 12 years and older with visual impairment associated with Leber’s hereditary optic neuropathy
24 April 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 26 Apr 2024
Melphalan flufenamide hydrochloride in combination with dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma
25 April 2024 - NICE is unable to make a recommendation on the use of melphalan flufenamide hydrochloride (Pepaxti) in combination ...
Posted by Michael Wonder on 25 Apr 2024
Children and teenagers with an aggressive form of brain cancer set to benefit after NICE recommends new life-extending drug combination treatment
24 April 2024 - A new targeted drug combination treatment, described as a ‘step-change in care’ for children and young ...
Posted by Michael Wonder on 24 Apr 2024
Pembrolizumab in combination with gemcitabine and cisplatin for the first-line treatment of patients with advanced biliary tract cancer
24 April 2024 - NICE is unable to make a recommendation on the use of pembrolizumab (Keytruda) in combination with cisplatin ...
Posted by Michael Wonder on 11 Apr 2024
170,000 people in England to have further treatment choice for preventing migraine attacks
11 April 2024 - In final draft guidance published today NICE has recommended atogepant, the first of a new type of ...
Posted by Michael Wonder on 11 Apr 2024
Children and young adults to benefit after NICE recommends personalised immunotherapy to treat blood cancer be made routinely available on the NHS
11 April 2024 - Innovative CAR-T therapy recommended to treat an aggressive form of leukaemia. ...
Posted by Michael Wonder on 10 Apr 2024
Cabozantinib maleate in combination with nivolumab for the first-line treatment of patients with advanced renal cell carcinoma
10 April 2024 - NICE has published final evidence-based recommendations on the use of cabozantinib maleate (Cabometyx) in combination with ...
Posted by Michael Wonder on 03 Apr 2024
Dostarlimab in combination with platinum-based chemotherapy for the treatment of patients with advanced or recurrent, high microsatellite instability or mismatch repair deficiency endometrial cancer
3 April 2024 - NICE has published final evidence-based recommendations on the use of dostarlimab (Jemperli) in combination with platinum-based ...
Posted by Michael Wonder on 02 Apr 2024
Vamorolone for the treatment of patients with Duchenne muscular dystrophy
28 March 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...